Terbutaline in myasthenia gravis: A pilot study

Journal of the Neurological Sciences

Volumn 277, Issue 1-2, 2009, Pages 150-154

  Soliven, Betty ^a   Rezania, Kourosh ^a   Gundogdu, Betul ^b   Harding Clay, Barbara ^a   Oger, Joel ^c   Arnason, Barry G W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adrenergic agonists; cAMP; Neuromuscular junction; Postsynaptic

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CYCLOSPORIN; PLACEBO; PREDNISONE; PYRIDOSTIGMINE; TERBUTALINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; GRIP STRENGTH; HUMAN; MALE; MYASTHENIA GRAVIS; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STATISTICAL ANALYSIS; TREATMENT RESPONSE; TREMOR; WILCOXON SIGNED RANKS TEST;

ADRENERGIC BETA-AGONISTS; ADULT; AGED; CHOLINESTERASE INHIBITORS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PILOT PROJECTS; PLACEBOS; PYRIDOSTIGMINE BROMIDE; TERBUTALINE; YOUNG ADULT;

EID: 58149291874     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.09.033     Document Type: Article

References (37)

1. Richman D.P., and Agius M.A. Treatment of autoimmune myasthenia gravis. Neurology 61 12 (2003) 1652-1661
2. Chelmicka-Schorr E., Kwasniewski M.N., and Czlonkowska A. Sympathetic nervous system modulates macrophage function. Int J Immunopharmacol 14 5 (1992) 841-846
3. Soliven B., and Wang N. Tumor necrosis factor-alpha regulates nicotinic responses in mixed cultures of sympathetic neurons and nonneuronal cells. J Neurochem 64 2 (1995) 883-894
4. Albuquerque E.X., Deshpande S.S., Aracava Y., Alkondon M., and Daly J.W. A possible involvement of cyclic AMP in the expression of desensitization of the nicotinic acetylcholine receptor. A study with forskolin and its analogs. FEBS Lett 199 1 (1986) 113-120
5. Bukharaeva E.A., Samigullin D., Nikolsky E., and Vyskocil F. Protein kinase A cascade regulates quantal release dispersion at frog muscle endplate. J Physiol 538 Pt 3 (2002) 837-848
6. Edgeworth H. The effect of ephedrine in the treatment of myasthenia gravis. JAMA 100 (1933) 1401
7. Bestue-Cardiel M., Saenz de Cabezon-Alvarez A., Capablo-Liesa J.L., Lopez-Pison J., Pena-Segura J.L., and Martin-Martinez J. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 65 1 (2005) 144-146
8. Slater C.R., Fawcett P.R., Walls T.J., Lyons P.R., Bailey S.J., and Beeson D. Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'. Brain 129 Pt 8 (2006) 2061-2076
9. Shinnick-Gallagher P., and Gallagher J.P. Ephedrine: a postsynaptic depressant drug at the mammalian neuromuscular junction. Neuropharmacology 18 10 (1979) 755-761
10. Sieb J.P., and Engel A.G. Ephedrine: effects on neuromuscular transmission. Brain Res 623 1 (1993) 167-171
11. Chelmicka-Schorr E., and Arnason B.G. Nervous system-immune system interactions. Res Publ Assoc Res Nerv Ment Dis 68 (1990) 67-90
12. Kohm A.P., and Sanders V.M. Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol Rev 53 4 (2001) 487-525
13. Chelmicka-Schorr E., Wollmann R.L., Kwasniewski M.N., Kim D.H., and Dupont B.L. The beta2-adrenergic agonist terbutaline suppresses acute passive transfer experimental autoimmune myasthenia gravis (EAMG). Int J Immunopharmacol 15 1 (1993) 19-24
14. Tindall R.S., Rollins J.A., Phillips J.T., Greenlee R.G., Wells L., and Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316 12 (1987) 719-724
15. Kaufman R.L., and Oger J. Antibody production by blood lymphocytes in myasthenia gravis: reduction in disease of long duration. Neurology 38 5 (1988) 818-821
16. Jonkers I., Swerup C., Pirskanen R., Bjelak S., and Matell G. Acute effects of intravenous injection of beta-adrenoreceptor- and calcium channel antagonists and agonists in myasthenia gravis. Muscle Nerve 19 8 (1996) 959-965
17. Confavreux C., Charles N., and Aimard G. Fulminant myasthenia gravis soon after initiation of acebutolol therapy. Eur Neurol 30 5 (1990) 279-281
18. Matell G., Bjelak S., Jonkers I., Pirskanen R., Van Vliet J., and Swerup C. Calcium channel and beta-receptor antagonists and agonists in MG. Ann N Y Acad Sci 841 (1998) 785-788
19. Chaney L.A., Rockhold R.W., Mozingo J.R., Hume A.S., and Moss J.I. Potentiation of pyridostigmine bromide toxicity in mice by selected adrenergic agents and caffeine. Vet Hum Toxicol 39 4 (1997) 214-219
20. Kuba K. Effects of catecholamines on the neuromuscular junction in the rat diaphragm. J Physiol 211 3 (1970) 551-570
21. Shyng S.L., Xu R., and Salpeter M.M. Cyclic AMP stabilizes the degradation of original junctional acetylcholine receptors in denervated muscle. Neuron 6 3 (1991) 469-475
22. Van der Kloot W., and Branisteanu D.D. Effects of activators and inhibitors of protein kinase A on increases in quantal size at the frog neuromuscular junction. Pflugers Arch 420 3-4 (1992) 336-341
23. Li Z., Forester N., and Vincent A. Modulation of acetylcholine receptor function in TE671 (rhabdomyosarcoma) cells by non-AChR ligands: possible relevance to seronegative myasthenia gravis. J Neuroimmunol 64 2 (1996) 179-183
24. Bukcharaeva E., Samigullin D., Nikolsky E.E., and Vyskocil F. Cyclic AMP synchronizes evoked quantal release at frog neuromuscular junctions. Physiol Res 49 4 (2000) 475-479
25. Cairns S.P., Westerblad H., and Allen D.G. Changes of tension and [Ca2+]i during beta-adrenoceptor activation of single, intact fibres from mouse skeletal muscle. Pflugers Arch 425 1-2 (1993) 150-155
26. Agius M.A., Checinski M.E., Richman D.P., and Chelmicka-Schorr E. Sympathectomy enhances the severity of experimental autoimmune myasthenia gravis (EAMG). J Neuroimmun 16 (1987) 11-12
27. Soliven B., and Nelson D.J. Beta-adrenergic modulation of K+ current in human T lymphocytes. J Membr Biol 117 3 (1990) 263-274
28. DeCoursey T.E., Chandy K.G., Gupta S., and Cahalan M.D. Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis?. Nature 307 5950 (1984) 465-468
29. Cahalan M.D., and Lewis R.S. Functional roles of ion channels in lymphocytes. Semin Immunol 2 2 (1990) 107-117
30. Hu X.X., Goldmuntz E.A., and Brosnan C.F. The effect of norepinephrine on endotoxin-mediated macrophage activation. J Neuroimmunol 31 1 (1991) 35-42
31. Zhang G.X., Xiao B.G., Bai X.F., van der Meide P.H., Orn A., and Link H. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol 162 7 (1999) 3775-3781
32. Goluszko E., Deng C., Poussin M.A., and Christadoss P. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J Neuroimmunol 122 1-2 (2002) 85-93
33. Wang H.B., Li H., Shi F.D., Chambers B.J., Link H., and Ljunggren H.G. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. Int Immunol 12 10 (2000) 1381-1388
34. Duan R.S., Wang H.B., Yang J.S., Scallon B., Link H., and Xiao B.G. Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis. J Autoimmun 19 4 (2002) 169-174
35. Christadoss P., and Goluszko E. Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. J Neuroimmunol 122 1-2 (2002) 186-190
36. Salomonsson S., and Lundberg I.E. Cytokines in idiopathic inflammatory myopathies. Autoimmunity 39 3 (2006) 177-190
37. Xu B.Y., Pirskanen R., and Lefvert A.K. Antibodies against beta1 and beta2 adrenergic receptors in myasthenia gravis. J Neuroimmunol 91 1-2 (1998) 82-88